Open AccessP498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG‐TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML‐001 TRIAL OF ORAL AZACITIDINE
Author(s) -
Wei A. H.,
Döhner H.,
Sayar H.,
Ravandi F.,
Montesinos P.,
Dombret H.,
Selleslag D.,
Porkka K.,
Jang J.H.,
Skikne B.,
Beach C.,
Prebet T.,
Zhang G.,
Risueño A.,
Ugidos Guerrero M.,
See W. L.,
Menezes D.,
Roboz G. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844880.16190.70
Subject(s) - medicine , azacitidine , randomization , gastroenterology , clinical endpoint , myeloid leukemia , cohort , chemotherapy , placebo , oncology , surgery , randomized controlled trial , pathology , gene expression , dna methylation , gene , biochemistry , chemistry , alternative medicine